New pill shows promise in early cancer trial
NCT ID NCT06923761
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests an experimental drug called GRWD5769, taken as a pill, for people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to check safety and find the right dose, and second, to see if the drug shrinks tumors when used alone or with another cancer medicine. About 300 adults will take part, and researchers will monitor side effects and tumor changes over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GRWD5769 (an experimental drug taken by mouth)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid cancers that have not responded to other therapies.
- What could go wrong
- This is an early, first-in-human trial, so the drug may not be safe or effective. Side effects are unknown, and the study is small, so results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alfred Health
RECRUITINGMelbourne, Australia
-
Austin Health
RECRUITINGHeidelberg, Australia
-
Blacktown Hospital
RECRUITINGBlacktown, Australia
-
Cancer Care Wollongong
RECRUITINGWollongong, Australia
-
Centre Eugène Marquis
RECRUITINGRennes, France
-
Centre Léon Bérard
RECRUITINGLyon, France
-
Christie NHS Foundation Trust
RECRUITINGManchester, United Kingdom
-
Clatterbridge Cancer Centre
RECRUITINGLiverpool, United Kingdom
-
Clinica Universitaria de Navarra Madrid
RECRUITINGMadrid, Spain
-
Clinica Universitaria de Navarra Pamplona
RECRUITINGPamplona, Spain
-
GenesisCare Research
WITHDRAWNAdelaide, Australia
-
Hammersmith Hospitals NHS Trust
RECRUITINGLondon, United Kingdom
-
Hospital Universitario Vall d'Hebrón (VHIO)
RECRUITINGBarcelona, Spain
-
Hospital Universitario Virgen de la Victoria
RECRUITINGMálaga, Spain
-
ICANS - Institut de Cancérologie Strasbourg
RECRUITINGStrasbourg, France
-
INCLIVA-Hospital Clínico Universitario de Valencia
RECRUITINGValencia, Spain
-
IUCT Oncopole - Institut Claudius Regaud
RECRUITINGToulouse, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
-
Institut Paoli-Calmettes
RECRUITINGMarseille, France
-
Institut de Cancérologie de l'Ouest (ICO)
RECRUITINGSaint-Herblain, France
-
Kinghorn Cancer Centre (KCC)
RECRUITINGDarlinghurst, Australia
-
Mater Research
RECRUITINGSouth Brisbane, Australia
-
Newcastle Upon Tyne Hospital
RECRUITINGNewcastle, United Kingdom
-
Royal Free Hospital
RECRUITINGLondon, United Kingdom
-
START Barcelona - Hospital HM Nou Delfos
RECRUITINGBarcelona, Spain
-
START Madrid - Centro Integral Oncológico Clara Campal (HM CIOCC)
RECRUITINGMadrid, Spain
-
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, Spain
-
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITINGBedford Park, Australia
-
Western General Hospital
RECRUITINGEdinburgh, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug IBI363 aims to supercharge immune system against tough cancers
- New drug cocktail aims to shrink Hard-to-Treat cancers
- New drug combo targets tough cancers in early trial
- New drug duo aims to fight Hard-to-Treat cancers
- New drug cocktail shows promise against tough cancers
- New combo therapy shows promise for Hard-to-Treat cancers